JP6145667B2 - アロディニア、痛覚過敏、自発痛、及び幻痛の治療 - Google Patents

アロディニア、痛覚過敏、自発痛、及び幻痛の治療 Download PDF

Info

Publication number
JP6145667B2
JP6145667B2 JP2014528860A JP2014528860A JP6145667B2 JP 6145667 B2 JP6145667 B2 JP 6145667B2 JP 2014528860 A JP2014528860 A JP 2014528860A JP 2014528860 A JP2014528860 A JP 2014528860A JP 6145667 B2 JP6145667 B2 JP 6145667B2
Authority
JP
Japan
Prior art keywords
seq
cometin
allodynia
hyperalgesia
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014528860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014529408A (ja
JP2014529408A5 (enExample
Inventor
ヨルゲンセン，イェスパ・ローラン
ヴァルベアウ，ラース・ウルレク
ヨハンセン，テイト・イ．
Original Assignee
ホーバ セラピューティクス アンパルトセルスカブ
ホーバ セラピューティクス アンパルトセルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ホーバ セラピューティクス アンパルトセルスカブ, ホーバ セラピューティクス アンパルトセルスカブ filed Critical ホーバ セラピューティクス アンパルトセルスカブ
Publication of JP2014529408A publication Critical patent/JP2014529408A/ja
Publication of JP2014529408A5 publication Critical patent/JP2014529408A5/ja
Application granted granted Critical
Publication of JP6145667B2 publication Critical patent/JP6145667B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2014528860A 2011-09-05 2012-09-05 アロディニア、痛覚過敏、自発痛、及び幻痛の治療 Active JP6145667B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161531024P 2011-09-05 2011-09-05
US61/531,024 2011-09-05
PCT/DK2012/050330 WO2013034157A1 (en) 2011-09-05 2012-09-05 Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain

Publications (3)

Publication Number Publication Date
JP2014529408A JP2014529408A (ja) 2014-11-13
JP2014529408A5 JP2014529408A5 (enExample) 2015-11-05
JP6145667B2 true JP6145667B2 (ja) 2017-06-14

Family

ID=46940179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528860A Active JP6145667B2 (ja) 2011-09-05 2012-09-05 アロディニア、痛覚過敏、自発痛、及び幻痛の治療

Country Status (8)

Country Link
US (2) US9474786B2 (enExample)
EP (1) EP2753347B1 (enExample)
JP (1) JP6145667B2 (enExample)
KR (1) KR102075881B1 (enExample)
CN (2) CN107596346A (enExample)
AU (1) AU2012306810B2 (enExample)
CA (1) CA2846511C (enExample)
WO (1) WO2013034157A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2195013B1 (en) 2008-07-24 2011-11-02 NsGene A/S Therapeutic use of a growth factor, metrnl
WO2019132624A1 (ko) * 2017-12-29 2019-07-04 주식회사 헬릭스미스 하이브리드 hgf 유전자가 도입된 aav(아데노-연관 바이러스) 벡터
CN110004223A (zh) * 2019-05-09 2019-07-12 苏州大学附属第一医院 一种用于预测早发型子痫前期发病的检测试剂盒
KR20240006581A (ko) * 2021-05-06 2024-01-15 호바 세라퓨틱스 에이피에스 화학요법-유도된 신경병성 통증의 예방 및 치료
CN118488846A (zh) * 2021-12-10 2024-08-13 霍巴治疗公司 伤害性疼痛的治疗

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
JP3015383B2 (ja) 1987-09-11 2000-03-06 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 形質導入した線維芽およびそれらの使用
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5156844A (en) 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
ES2107537T3 (es) 1991-04-25 1997-12-01 Univ Brown Res Found Vehiculo inmunoaislante biocompatible implantable para suministrar productos terapeuticos seleccionados.
DE69332406T2 (de) 1992-04-30 2003-06-26 Naamloze Vennootschap Innogenetics S.A., Gent Polypeptide und peptide dafür kodierende nukleinsaüre und ihre verwendung im zusammenhang mit tumortherapie, entzündung oder immunology
DK0802800T3 (da) 1993-08-12 2002-10-07 Neurotech Sa Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5904144A (en) 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
PT1080202E (pt) 1998-05-27 2006-05-31 Avigen Inc Distribuicao de vectores aav codificando aadc intensificada por conveccao
AU7452300A (en) 1999-10-01 2001-05-10 Kyowa Hakko Kogyo Co. Ltd. Shear stress-response dna
AU1395801A (en) 1999-11-30 2001-06-12 Innogenetics N.V. New uses of suppressive macrophage activation factors
CA2395676A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2395885A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
EP1572987A4 (en) 2000-02-03 2005-11-30 Nuvelo Inc NUCLEIC ACIDS AND POLYPEPTIDES
CA2403901A1 (en) 2000-05-02 2001-11-08 Human Genome Sciences, Inc. 29 human secreted proteins
CN1525866B (zh) 2001-03-28 2013-05-29 比奥根艾迪克Ma公司 神经胚活素多肽的治疗作用
US20050208062A1 (en) 2001-12-21 2005-09-22 Yongming Sun Compositions and methods relating to hepatic specific genes and proteins
AU2003294217A1 (en) 2002-08-29 2004-05-04 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
EP1599607A2 (en) 2003-03-04 2005-11-30 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
NZ550542A (en) * 2004-03-30 2009-03-31 Nsgene As Therapeutic use of a growth factor, NsG33
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
CN1982454A (zh) * 2005-12-15 2007-06-20 中国医学科学院北京协和医院 一种骨质疏松相关基因及其编码蛋白和用途
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP2195013B1 (en) 2008-07-24 2011-11-02 NsGene A/S Therapeutic use of a growth factor, metrnl
AU2011307488B2 (en) * 2010-10-01 2015-08-20 Hoba Therapeutics Aps Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain

Also Published As

Publication number Publication date
AU2012306810A1 (en) 2014-03-13
CN104105501A (zh) 2014-10-15
JP2014529408A (ja) 2014-11-13
KR20140068148A (ko) 2014-06-05
KR102075881B1 (ko) 2020-02-11
US20150231208A1 (en) 2015-08-20
US9861682B2 (en) 2018-01-09
CN107596346A (zh) 2018-01-19
AU2012306810B2 (en) 2017-09-28
EP2753347A1 (en) 2014-07-16
CA2846511A1 (en) 2013-03-14
HK1199395A1 (en) 2015-07-03
US20170143794A1 (en) 2017-05-25
WO2013034157A1 (en) 2013-03-14
CA2846511C (en) 2021-07-13
US9474786B2 (en) 2016-10-25
EP2753347B1 (en) 2016-08-03
CN104105501B (zh) 2017-10-20

Similar Documents

Publication Publication Date Title
KR100271247B1 (ko) 청력손실 치료용 제약학적 조성물
EP1993589B1 (en) Treatments for neurological disorders
JP6247734B2 (ja) アロディニア、痛覚過敏、自発痛及び幻肢痛の処置
JP6145667B2 (ja) アロディニア、痛覚過敏、自発痛、及び幻痛の治療
ES2374971T3 (es) Uso de polipéptidos de neublastina para el tratamiento del dolor neuropático.
HK1199395B (en) Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain
US20090136552A1 (en) Growth factors nsg28, nsg30, and nsg32
CA3239550A1 (en) Treatment of nociceptive pain
DE10317369A1 (de) proNGF als pharmazeutisch wirksames Mittel zur Behandlung demyelinisierender Erkrankungen
HK1186412B (en) Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150902

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170315

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170410

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170427

R150 Certificate of patent or registration of utility model

Ref document number: 6145667

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250